-
公开(公告)号:US20080319191A1
公开(公告)日:2008-12-25
申请号:US12229402
申请日:2008-08-22
申请人: Judith Aronhime , Tamas Koltai , Viviana Braude , Serguei Fine , Tamar Niddam
发明人: Judith Aronhime , Tamas Koltai , Viviana Braude , Serguei Fine , Tamar Niddam
IPC分类号: C07D413/02
CPC分类号: A61K31/535 , C07D263/20
摘要: The present invention provides a novel crystalline form of linezolid referred to herein as Form IV as well as methods for the preparation and use of Form IV. The present invention provides pharmaceutical compositions that comprise therapeutically effective amounts of Form IV that can be used to treat patients suffering from gram-positive bacterial infections. Various processes for making crystalline linezolid Form IV are disclosed.
摘要翻译: 本发明提供了本文称为形式IV的利奈唑胺的新型结晶形式以及制备和使用形式IV的方法。 本发明提供包含治疗有效量的形式IV的药物组合物,其可用于治疗患有革兰氏阳性细菌感染的患者。 公开了制备结晶利奈唑胺形式IV的各种方法。
-
公开(公告)号:US20060142283A1
公开(公告)日:2006-06-29
申请号:US11171098
申请日:2005-06-29
申请人: Judith Aronhime , Tamas Koltai , Viviana Braude , Serguei Fine , Tamar Niddam
发明人: Judith Aronhime , Tamas Koltai , Viviana Braude , Serguei Fine , Tamar Niddam
IPC分类号: A61K31/535
CPC分类号: A61K31/535 , C07D263/20
摘要: The present invention provides a novel crystalline form of linezolid referred to herein as Form IV as well as methods for the preparation and use of Form IV. The present invention provides pharmaceutical compositions that comprise therapeutically effective amounts of Form IV that can be used to treat patients suffering from gram-positive bacterial infections. Various processes for making crystalline linezolid Form IV are disclosed.
摘要翻译: 本发明提供了本文称为形式IV的利奈唑胺的新型结晶形式以及制备和使用形式IV的方法。 本发明提供包含治疗有效量的形式IV的药物组合物,其可用于治疗患有革兰氏阳性细菌感染的患者。 公开了制备结晶利奈唑胺形式IV的各种方法。
-
公开(公告)号:US20060111350A1
公开(公告)日:2006-05-25
申请号:US11171579
申请日:2005-06-29
申请人: Judith Aronhime , Tamas Koltai , Viviana Braude , Serguei Fine , Tamar Niddam
发明人: Judith Aronhime , Tamas Koltai , Viviana Braude , Serguei Fine , Tamar Niddam
IPC分类号: A61K31/5377 , C07D413/02
CPC分类号: C07D263/20
摘要: Novel crystalline forms of Linezolid, designated as Form TIII, Form V, Form VI, Form IX, Form X, Form XII, Form XIV, Form XVII, and Form XVIII, are disclosed. The novel crystalline forms are characterized by powder X-ray diffraction, FTIR and FTRaman spectroscopy, and differential scanning calorimetry. Methods of preparing the novel crystalline forms, pharmaceutical compositions comprising the novel crystalline forms, and methods of using the novel crystalline forms to treat gram positive bacterial infections are also described. Amorphous Linezolid is also disclosed.
摘要翻译: 公开了新型晶体形式的利奈唑胺,称为形式TIII,形式V,形式VI,形式IX,形式X,形式XII,形式XIV,形式XVII和形式XVIII。 新型结晶形式的特征在于粉末X射线衍射,FTIR和FTRaman光谱学以及差示扫描量热法。 还描述了制备新结晶形式的方法,包含新结晶形式的药物组合物,以及使用新型结晶形式治疗革兰氏阳性细菌感染的方法。 还公开了无定形利奈唑胺。
-
-